MOTS-c is a mitochondrial-derived peptide that has attracted significant attention in metabolic and longevity research since its discovery. This article provides an educational overview of what the published scientific literature reports about MOTS-c, its origin, and its mechanisms of interest. All information below is provided strictly for research and informational purposes.
What is MOTS-c?
MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a 16-amino-acid peptide, notable as one of the first peptides discovered to be encoded by mitochondrial DNA rather than nuclear DNA. It was first reported in 2015. Its discovery is significant in research terms because it revealed that mitochondria can produce signalling molecules that communicate with the rest of the cell. It is typically supplied as a lyophilised powder for research use.
Mechanisms of interest
Scientific interest in MOTS-c centres on its role in cellular energy regulation. The published literature describes its study in relation to:
- AMPK pathway activation — research describes MOTS-c as acting through the folate–AICAR–AMPK pathway, a central regulator of cellular energy metabolism.
- Glucose metabolism and insulin sensitivity — studies in research models have examined its influence on glucose uptake in skeletal muscle and on insulin sensitivity.
- Exercise-related signalling — research notes that circulating MOTS-c levels increase with exercise in study subjects, leading to its description in the literature as an "exercise-mimetic" research model.
- Nuclear gene regulation — studies report that MOTS-c can translocate to the cell nucleus and influence the expression of stress-adaptation genes.
What the research has reported
MOTS-c is the subject of a growing body of preclinical research, spanning metabolic homeostasis, ageing, and exercise-related signalling. Research notes that endogenous MOTS-c levels have been observed to decline with age in study models. As with many peptides in this category, the research is predominantly preclinical and mechanistic, and the body of human clinical data remains limited and developing.
Regulatory status in Australia
MOTS-c has not been approved by the Therapeutic Goods Administration (TGA), is not listed on the Australian Register of Therapeutic Goods (ARTG), and is not approved for therapeutic use. It is supplied strictly as a research compound.
Important disclaimer
This article is provided for informational and laboratory-research purposes only. MOTS-c is supplied strictly as a research compound, for in-vitro laboratory research use only. It is not for human or animal consumption. Nothing in this article constitutes medical advice, nor a recommendation for use in humans. Always refer to current published literature and applicable regulations.